CRP and renal cell carcinoma: It is worth noting that in the clinical practice of treating RCC, some inflammatory markers have preliminarily proved their effectiveness in molecular targeted therapy or immunotherapy and the prediction of patient survival results, including routine C reactive protein, Neutrophil-to-lymphocyte ratio (NLR) and creatinine, but it is undeniable that such biomarkers are susceptible to immediate effects of infectious diseases and treatment modalities (such as drug-induced myelosuppression).[33] In contrast, the skeletal muscle index of sarcopenia is more objective and has good repeatability.